Promoter-Specific Variants in NeuroD1 and H3K4me3 Coincident Regions and Clinical Outcomes of Small Cell Lung Cancer
Seung-Soo YOO; Sunwoong LEE; Jin-Eun CHOI; Mi-Jeong HONG; Sook-Kyung DO; Jang-Hyuck LEE; Won-Kee LEE; Ji-Eun PARK; Yong-Hoon LEE; Sun-Ha CHOI; Hyewon SEO; Jaehee LEE; Shin-Yup LEE; Seung-Ick CHA; Chang-Ho KIM; Hyo-Gyoung KANG; Jae-Yong PARK.
Journal of Korean Medical Science
; : e381-2023.
Artículo
en Inglés
| WPRIM | ID: wpr-1001170
Background@#Neurogenic differentiation 1 (NeuroD1) is a representative small cell lung cancer (SCLC) transcription regulator involved in the carcinogenesis and behavior of SCLC.Histone modifications play an important role in transcription, and H3 lysine 4 trimethylation (H3K4me3) is primarily associated with promoter regions. @*Methods@#We investigated the association between single nucleotide polymorphisms (SNPs) in NeuroD1 and H3K4me3 coincident regions, selected using ChIP sequencing (ChIP-seq), and the clinical outcomes of 261 patients with SCLC. @*Results@#Among 230 SNPs, two were significantly associated with both the chemotherapy response and overall survival (OS) of patients with SCLC. RNF145 rs2043268A>G was associated with worse chemotherapy response and OS (under a recessive model, adjusted odds ratio [aOR], 0.50, 95% confidence interval [CI], 0.26–0.94, P = 0.031, and adjusted hazard ratio [aHR], 1.88, 95% CI, 1.38–2.57, P G was also associated with worse chemotherapy response and OS (under a dominant model, aOR, 0.47, 95% CI, 0.23–0.99, P = 0.046, and aHR, 2.03, 95% CI, 1.47–2.82, P G and CINP rs762105A>G were associated with clinical outcomes in patients with SCLC and also affected the promoter activity of each gene.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados